CXCL10/IP-10/CRG-2 Antibody Summary
Recombinant human CXCL10/INP10 expressed in E. coli.
CXCL10/INP10
IgG
Polyclonal
Goat
CXCL10
Protein G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Western Blot 1:100-1:2000
- ELISA 1:100-1:2000
Predicted molecular weight: 8.7 kDa. Not tested in other applications.Optimal dilutions/concentrations should be determined by the end user.
Reactivity Notes
Cross-reacts with Human. Not yet tested in other species.
Packaging, Storage & Formulations
Store at -20C. Avoid freeze-thaw cycles.
PBS and 5% Trehalose
No Preservative
1.0 mg/ml
Protein G purified
Alternate Names for CXCL10/IP-10/CRG-2 Antibody
- C7
- chemokine (C-X-C motif) ligand 10
- CRG2
- CRG-2
- CXCL10
- gIP-10
- IFI10
- INP10
- IP-10
- mob-1
- SCYB10
Background
IP-10 is a member of the C-X-C, or alpha chemokine class. It does not contains the ELR domain immediately preceding the first cysteine residue near the amino terminus. Other chemokines in this group include mouse CRG, Mig, PBSF/SDF-1, and PF4. These chemokines act primarily as chemoattractants and activate monocytes, dendritic cells, T lymphocytes, natural killer cells, B lymphocytes, basophils, and eosinophils. IP-10 was originally identified as an IFN-gamma- inducible gene in monocytes, fibroblasts, and endothelial cells. IP-10 is a chemoattractant for activated T lymphocytes. It is a potent inhibitor of angiogenesis and displays a thymus-dependent antitumor effect. IP-10 is an approximately 8.7 kDa polypeptide of 78 amino acids. The precursor form of human IP-10 consists of 98 amino acids. To generate the mature IP-10, the precursor cleaves its 21 amino acid signal peptide. Human IP-10 shows 67% amino acid homology to mouse CRG-2.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
product targets :　Metabolic Disease inhibitors